Anaphore is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Our novel Atrimer™ drug candidates are engineered from a fully-human serum protein that is naturally secreted as a trimeric structure of approximately 60 kilodaltons.


Date Title Link to PDF file

May 14, 2009 Anaphore Announces $13 Million Second Closing to Series A Financing

PDF File

January 7, 2009 Anaphore Announces $25 Million Series A Financing

PDF File

April 15, 2008 Anaphore Receives $8M In Financing

 

Our proprietary TrimerX™ protein engineering platform provides multiple approaches to generate Atrimer™ protein therapeutics with biological, manufacturing and commercial advantages over traditional drugs such as antibodies, smaller protein scaffolds, and small molecules.

Discover More

Creating places that enhance the human experience.


We always put people and nature at the center of our projects.
12
Useful options
45
Beautiful snippets
8
Amazing pages

Building Castle in Cloud

When designing an architectural concept, we take into account the nine criteria that Zumthor considers to be important in creating an architectural atmosphere.

As 436 clients before you, let’s work together